Calliditas Therapeutics AB has appointed Frank Bringstrup as head of regulatory affairs as its lead product for IgA nephropathy nears registration. Dr Bringstrup was previously with Novo Nordisk A/S where he led the regulatory submissions in Europe and the US for NovoEight, a treatment for blood disorders. Dr Bringstrup qualified as a medical doctor at the University of Copenhagen, received a diploma in business administration from Warwick University, and has done post-graduate studies in public health medicine at the National Board of Health in Denmark.
Calliditas announced the appointment on 14 January 2019.
Copyright 2019 Evernow Publishing Ltd.